stoxline Quote Chart Rank Option Currency Glossary
Pluristem Therapeutics Inc. (PSTI)
1  -0.03 (-2.91%)    07-26 00:00
Open: 1.02
High: 1.0401
Volume: 170,627
Pre. Close: 1.03
Low: 0.9595
Market Cap: 41(M)
Technical analysis
2022-11-18 4:23:58 PM
Short term     
Mid term     
Targets 6-month :  1.21 1-year :  1.41
Resists First :  1.04 Second :  1.21
Pivot price 1
Supports First :  0.99 Second :  0.95
MAs MA(5) :  1 MA(20) :  1
MA(100) :  1.01 MA(250) :  1.45
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  50.2 D(3) :  50.2
RSI RSI(14): 57.3
52-week High :  2.76 Low :  0.68
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PSTI ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.04 - 1.05 1.05 - 1.05
Low: 0.95 - 0.95 0.95 - 0.96
Close: 0.99 - 1 1 - 1.01
Company Description

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Headline News

Tue, 09 Apr 2024
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient - Yahoo Movies Canada

Mon, 25 Jul 2022
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its ... - GlobeNewswire

Tue, 08 Mar 2022
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture - BioSpace

Tue, 18 Jan 2022
Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to ... - PR Newswire

Mon, 10 Jan 2022
Biotechnology Company Pluristem, and Israel's Largest Food - GlobeNewswire

Mon, 19 Jul 2021
Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 32 (M)
Held by Insiders 2.759e+007 (%)
Held by Institutions 7.2 (%)
Shares Short 487 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.605e+007
EPS Est Next Qtrly -0.1
EPS Est This Year -0.35
EPS Est Next Year -0.35
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -20 %
Return on Assets (ttm) 212.8 %
Return on Equity (ttm) -37.4 %
Qtrly Rev. Growth 234000 %
Gross Profit (p.s.) 0
Sales Per Share -45.32
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -38 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 1.2
Stock Dividends
Dividend 0
Forward Dividend 391400
Dividend Yield 0%
Dividend Pay Date 2019-07-24
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android